Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J. Ngaimisi E, et al. Among authors: bertilsson l. PLoS One. 2013 Jul 5;8(7):e67946. doi: 10.1371/journal.pone.0067946. Print 2013. PLoS One. 2013. PMID: 23861838 Free PMC article. Clinical Trial.
Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS. Habtewold A, et al. Among authors: bertilsson l. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28559276 Free PMC article.
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E. Mugusi S, et al. Among authors: bertilsson l. Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12. Eur J Clin Pharmacol. 2018. PMID: 30003275 Free PMC article.
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E. Ngaimisi E, et al. Among authors: bertilsson l. Clin Pharmacol Ther. 2011 Sep;90(3):406-13. doi: 10.1038/clpt.2011.129. Epub 2011 Aug 3. Clin Pharmacol Ther. 2011. PMID: 21814190 Clinical Trial.
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy U. Ngaimisi E, et al. Among authors: bertilsson l. J Antimicrob Chemother. 2014 Dec;69(12):3311-9. doi: 10.1093/jac/dku286. Epub 2014 Aug 4. J Antimicrob Chemother. 2014. PMID: 25096076
340 results